Travere Therapeutics

TVTX

Market cap $4.38B

Travere Therapeutics, Inc. (TVTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal segmental glomerulosclerosis (FSGS). Patients who initiated FILSPARI in the double-blind period and remained on therapy in the OLE maintained durable reductions in proteinuria, resulting in further achievement of clinically meaningful low proteinuria thresholds over time. Pati.

Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines Transcript

Travere Therapeutics said on Tuesday it has signed a licensing pact with privately held ​biotech Everest Medicines to develop and ‌commercialize an experimental kidney disease drug in a deal worth up to $1.14 billion.

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in all markets outside China and certain countries in East and Southeast Asia. “Civorebrutinib represents a strategic and complementary.

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,088, titled “Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders,” directed to certain methods of using FILSPARI® (sparsentan) in IgA nephropathy. Upon issuance, the patent is expected to provide U.S. patent coverage for certain methods of using sparsentan.

Travere Therapeutics, Inc. (TVTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 18,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 30,800 shares of its common stock. These inducement s.

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2026 Health Care Conference Presenting on Wednesday, May 13, 2026, at 5:20 p.m. ET (2:20 p.m. PT) 2026 Jefferies Global Healthcare Conference Presenting on Wednesday, June 3, 2026, at 8:45 a.m. ET Goldman Sachs 47th Annual Global Healthcare Conference 2026 Presenting on Monday, June 8, 2026, at 11:20 a.m. E.

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the “Notes”). The sale of the Notes is expected to close on May 11, 2026, subject to customary closing conditions. The aggregate principal amount of the offering was increased from the previously announced offering size of $400.0 million. Travere also granted the underwriters of the.